Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

INVO Fertility (IVF) Shares Outstanding (Weighted Average) (2016 - 2025)

INVO Fertility (IVF) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 3093.75% to $3.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Sep 2025, up 3093.75% year-over-year, with the annual reading at $309539.0 for FY2024, 159.54% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $3.4 million at INVO Fertility, up from $299114.0 in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $12.1 million in Q1 2022, with the low at $100276.0 in Q2 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $3.4 million, with a median of $622507.0 recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) tumbled 94.83% in 2023, then surged 3093.75% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $10.6 million in 2021, then tumbled by 94.3% to $606130.0 in 2022, then crashed by 80.32% to $119264.0 in 2023, then surged by 159.54% to $309539.0 in 2024, then soared by 1013.79% to $3.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $3.4 million, $299114.0, and $1.4 million for Q3 2025, Q2 2025, and Q1 2025 respectively.